PROPEL: Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain

Sponsor
University of Connecticut (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03637998
Collaborator
National Institute of Nursing Research (NINR) (NIH)
40
1
1
44.3
0.9

Study Details

Study Description

Brief Summary

This pilot project will provide an understanding of the contextual variables responsible for chronic low back pain. These variables include, genetic variation, pain sensitivity, reactivity, pain catastrophizing, perceived stress and kinesiphobia. The purpose is to understand the initial efficacy of self-management (SM) strategies on each of these contextual variables, in an effort to inform a personalized approach to managing chronic low back pain and its effect on improved health outcomes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Problem-solving Pain to Enhance Living Well (PROPEL)
N/A

Detailed Description

Chronic low back pain (cLBP) is the second most frequent chronic pain condition in the United States and results in billions of dollars each year in health care expenses, disability and lost productivity. A major factor that contributes to the refractory nature of cLBP is enhanced pain sensitivity, which is an altered state of pain processing that amplifies pain sensation and impairs descending pain inhibition. Enhanced pain sensitivity in patients who develop cLBP is associated with altered expression of pro-nociceptive and inflammatory genes. On the other hand, regular physical activity of at least moderate intensity for 150 or more minutes per week is recommended to reduce pain severity and improve function in individuals with cLBP. Therefore, a deeper mechanistic understanding of the effect of physical activity on the neurophysiologic and gene transcription alterations that characterize cLBP may inform more specific treatment options to optimize pain reduction and reduce the risk of pain chronicity.

The purpose of this longitudinal cohort pilot study is to examine the feasibility, acceptability, and preliminary efficacy of the Problem-solving Pain to Enhance Living Well (PROPEL) self-management (SM) intervention on cLBP. This pre-post intervention study will recruit 40 community dwelling adults (age 18 - 60 years old) with cLBP. They will receive electronic video modules focused on cLBP SM knowledge and weekly phone consultations to facilitate monitoring and problem-solving. All participants will be assessed for primary outcomes including cLBP SM behaviors, physical activity, pain severity and interferance, and pain sensitivity at baseline and every 2 weeks for 12 weeks. The study will examine differential neurophysiologic and gene expression profiles between participants with cLBP at 12-weeks post-intervention and correlate these outcome measures to total duration of physical activity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Impact of Physical Activity on the Neurophysiologic and Gene Expression Profiles of Chronic Low Back Pain: A Longitudinal Study Protocol
Actual Study Start Date :
Sep 21, 2018
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: PROPEL

The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.

Behavioral: Problem-solving Pain to Enhance Living Well (PROPEL)
PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit.

Outcome Measures

Primary Outcome Measures

  1. Change in physical activity [Baseline, 2, 4, 6, 8, 10 and 12 weeks]

    Fitbit for activity tracker

Secondary Outcome Measures

  1. Change in gene expression profiles [Baseline and 12 weeks post-intervention]

    RNA sequencing

  2. Change in pain sensitivity [Baseline and 12 weeks post-intervention]

    Quantitative sensory testing

  3. Relationship between pain self-management and pain severity [Baseline, 2, 4, 6, 8, 10 and 12 weeks]

    Change over time through questionnaires

  4. Relationship between pain self-management and pain interferance [Baseline, 2, 4, 6, 8, 10 and 12 weeks]

    Change over time through questionnaires

  5. Relationship between pain self-management and quality of life [Baseline, 2, 4, 6, 8, 10 and 12 weeks]

    Change over time through questionnaires

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • be 18-60 years of age;

  • have nonspecific cLBP (≥4 on the numeric rating scale; NRS) present for at least 3 out of the last 6 months and ≥ half the days in the past 6 months;

  • comprehend English (due to lack of reliability and validity of study instruments and the intervention in non-English populations).

  • Have daily access to a computer, tablet or smartphone with access to internet

  • Have less than 150 minutes of moderate physical activity a week

  • Be willing to wear activity tracker for 12 weeks

Exclusion Criteria:
  • Chronic pain at another site or associated with a painful condition (eg., fibromyalgia, neuropathy, rheumatoid arthritis)

  • history of comorbidities that affect sensorimotor function (eg., multiple sclerosis, cancer, spinal cord injury, diabetes)

  • previous spinal surgery within last 1 year

  • presence of neurological deficits such as weakness in the lower extremities (motor strength 4/5 of quads, glutes, hamstrings, EHL)

  • bowel or bladder dysfunction such as difficulty voiding or incontinence

  • sciatica or (+) leg raise

  • positive Romberg test

  • being pregnant or within 3 months postpartum

  • history of psychological disorders (major depression, bipolar disorder, schizophrenia)

  • identification of any "red flag" condition in the volunteer's past medical history that suggests specific LBP as determined by Dr. Kim such as conditions or medications that can affect pain sensitivity

  • injury to non-dominant hand or presence of open skin lesions, disturbed sensation, carpal tunnel or rash

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Connecticut Storrs Connecticut United States 06269

Sponsors and Collaborators

  • University of Connecticut
  • National Institute of Nursing Research (NINR)

Investigators

  • Principal Investigator: Kyounghae Kim, PhD, University of Connecticut
  • Study Director: Angela Starkweather, PhD, University of Connecticut

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Wanli Xu, Assistant Professor, University of Connecticut
ClinicalTrials.gov Identifier:
NCT03637998
Other Study ID Numbers:
  • H18-086
  • 5P20NR016605
First Posted:
Aug 20, 2018
Last Update Posted:
Sep 28, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wanli Xu, Assistant Professor, University of Connecticut
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 28, 2021